Thrombolytic Therapy: Clot Dissolution for Acute Ischemic Events
Thrombolytic therapy (fibrinolysis) uses plasminogen activators to dissolve occlusive thrombi, restoring perfusion.
Indications (Time-Critical)
- Acute ischemic stroke: IV alteplase ≤4.5 hr (selected ≤9 hr with imaging)
- STEMI: If PCI unavailable ≤12 hr; door-to-needle ≤30 min
- Massive PE: Hemodynamic instability
- Acute limb ischemia / arterial thrombosis
Agents
| Agent | Source | Mechanism | Key Feature |
|---|---|---|---|
| Alteplase (tPA) | Recombinant | Fibrin-specific: binds fibrin → converts plasminogen → plasmin | Standard for stroke/STEMI |
| Tenecteplase (TNK) | Modified tPA | Longer half-life, bolus dosing | STEMI preferred; stroke trials ongoing |
| Reteplase | Modified tPA | Less fibrin-specific, double bolus | STEMI |
| Streptokinase | Bacterial | Non-fibrin-specific; antigenic | Low cost; not for repeat use |
| Urokinase | Human kidney / recombinant | Direct plasminogen activator | Catheter-directed thrombosis |
Major Risk
Intracranial hemorrhage (ICH): ~3–6% in stroke; higher with age, HTN, large infarct, anticoagulation.
Contraindications
- Active bleeding, recent surgery/trauma, hemorrhagic stroke, aortic dissection, severe uncontrolled HTN
Benefit-risk assessment must be rapid and documented.
Blood Disorders - Related Articles
- Post-Blood Draw Soreness: Causes, Risks & What to Watch For
- Leukocytosis: Mechanisms, Types & Clinical Workup of Elevated WBC
- Heparin Alternatives: Understanding Options & Recent Concerns
- Blood Plasma Composition and Functions: A Comprehensive Overview
- Iron Deficiency Anemia: Symptoms, Causes & Early Signs
- Gas Embolism: Clinical Presentation and Emergency Response
- Natural Ways to Support Healthy Arteries: The Role of Cayenne Pepper
